Abbott India Q4 Review - Key Therapies Report Robust Sales Improvement; Positive Outlook: Axis Securities

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Axis Securities Report.Abbott India Ltd. reported revenue growth of 14.9% in Q4 FY22, outpacing the Indian pharma industry, (source: All Indian Origin Chemists and Distributors) growth of 3.9%. It was majorly driven by sales improvement in key therapies such as gasteroinsteinal (up 18.3% YoY) and hormones (up 5.0% YoY). Duphaston (gynecological) Q4 FY22 sales stabilised to Rs 282 crore, (source: AIOCD), reporting a de-growth of 10.0% YoY. Earlier, Mankind launched 'Dydrogesterone' in competition with Duphaston which resulted in a decrease in Duphaston sales. Abbott India’s gross margins improved by 330 basis points due to a richer product mix and passing on the increase in raw material prices. However, Ebitda margins improved by 465 bps due to an improvement in gross margins and a fall in other expenses. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Abbott India Q4 Review - Key Therapies Report Robust Sales Improvement; Positive Outlook: Axis Securities

Abbott India Q4 Review - Key Therapies Report Robust Sales Improvement; Positive Outlook: Axis Securities

Choose a plan